New initiatives in critical care: distinguishing hype from hope

Area of Science:

• Critical care medicine
• Clinical trial design
• Biostatistics

Background:

• Frustration exists regarding slow therapeutic agent development and failed investigator-initiated trials in critical care.
• Proposed solutions include personalized medicine, "omic" technologies, addressing treatment effect heterogeneity, and adaptive trial designs.

Purpose of the Study:

• To critically examine proposed new directions in critical care research within the context of analyzing randomized controlled trials (RCTs).
• To evaluate the practical application and limitations of personalized medicine, heterogeneity resolution, and adaptive trial designs.

Main Methods:

• Analysis of existing randomized controlled trials (RCTs).
• Examination of the challenges in accounting for center effects in RCT analysis.
• Critique of the random effects approach and adaptive trial design implementation.

Main Results:

• Treatment effect heterogeneity, a significant issue in critical care, is also prevalent in cancer oncology.
• Personalized medicine's appeal is questioned as treatments are identified at group/stratified levels, not individual ones.
• Analysis of RCTs is hindered by issues with center effect accounting and rejection of the random effects approach.
• Adaptive trial designs are currently more rhetorical than substantive.

Conclusions:

• The proposed advancements in critical care research, including personalized medicine and adaptive trials, face significant methodological and analytical challenges.
• Addressing treatment effect heterogeneity requires more robust statistical approaches beyond current implementations.
• Further substantive development is needed for adaptive trial designs to be effective in critical care research.